GlassScriptPhysician profile
Naseer Ahmad
NPI 1295804250
$1,006.26
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $702 · 2021: $94.66 · 2024: $27.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $76.59 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $64.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $56.70 | 2020-2024 | Ojjaara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.90 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $51.32 | 2019-2020 | |
| Amgen INC. | $48.56 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $45.16 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $44.69 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $42.55 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.32 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.56 | 2020 | |
| Incyte Corporation | $35.62 | 2020 | |
| Secura Bio, INC. | $27.82 | 2020 | |
| Alexion Pharmaceuticals, INC. | $25.23 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $24.58 | 2020 | |
| Verastem, INC. | $24.21 | 2020 | |
| Eisai INC. | $23.26 | 2020 | |
| Celgene Corporation | $22.99 | 2020 | |
| Taiho Oncology, INC. | $22.37 | 2020 | |
| Genzyme Corporation | $22.37 | 2020 | |
| Seagen INC. | $20.91 | 2020 | |
| Janssen Biotech, INC. | $20.60 | 2020 | |
| Lilly USA, LLC | $19.45 | 2020 | |
| Astellas Pharma US INC | $19.12 | 2020 | |
| Clovis Oncology, INC. | $18.92 | 2019 | |
| Pfizer INC. | $18.87 | 2021 | |
| Rigel Pharmaceuticals, INC. | $17.48 | 2020 | |
| Puma Biotechnology, INC. | $14.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naseer Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.